1
|
Lucas JT, Faught AM, Hsu CY, Wilson LJ, Guo Y, Li Y, Khan R, Becksfort JB, LeVine DA, Ismael Y, Darrow K, Moskvin VP, Pirlepesov F, Klimo P, Elijovich L, Indelicato DJ, Boop FA, Merchant TE. Pre- and Post-therapy Risk Factors for Vasculopathy in Pediatric Craniopharyngioma Patients Treated with Surgery and Proton Radiotherapy. Int J Radiat Oncol Biol Phys 2022; 113:152-160. [PMID: 34990778 DOI: 10.1016/j.ijrobp.2021.12.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 10/26/2021] [Accepted: 12/27/2021] [Indexed: 10/19/2022]
Abstract
PURPOSE Vasculopathy (VAS) is a significant complication associated with radiotherapy in patients treated for brain tumors. We studied the type, location, severity, timing, and resolution of VAS in children with craniopharyngioma treated with proton radiotherapy (PRT) and evaluated predictors of stenosis (STN) using a novel patient and imaging-based modelling approach. MATERIALS/METHODS Children with craniopharyngioma (N=94) were treated with 54 GyRBE PRT on a clinical trial NCTXXXXXXXX.1 We evaluated VAS type, location, severity, and resolution. VAS events were segmented and related to their location, operative corridor, PRT dose, and vascular territory to facilitate Mixed Effect Logistic Regression Modelling of spatial predictors of STN events. RESULTS Forty-five (47.9%) patients had 111 instances of confirmed VAS (pre-PRT N = 37, 33.3%). The median time to post-PRT VAS was 3.41 years (95% CI 1.86-6.11). Stenosis events were observed post-PRT in 23.4% (N=22) patients. Post-PRT VAS was detected by cerebral angiogram in 9.6% (N=9), severe in 4.3% (N=4), and compensated on perfusion in 2.1% (N=2). Revascularization was required for 5 (5.3%) patients. Post-surgical, pre-PRT VAS, and PRT dose to unperturbed vessels were predictive of STN. The impact of PRT on STN was negligible within the surgical corridor. CONCLUSIONS VAS often precedes PRT and was the strongest predictor of post-PRT STN. The adverse impact of PRT on STN was only apparent in unperturbed vasculature beyond the operative corridor.
Collapse
Affiliation(s)
- John T Lucas
- Department of Radiation Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105.
| | - Austin M Faught
- Department of Radiation Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105
| | - Chih Yang Hsu
- GlaxoSmithKline, 812 Springdale Drive, Exton, PA 19341
| | - Lydia J Wilson
- Department of Radiation Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105
| | - Yian Guo
- Department of Biostatistics, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105
| | - Yimei Li
- Department of Biostatistics, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105.
| | - Raja Khan
- Department of Neurology, St. Jude Children's Research Hospital, Memphis, TN 38105
| | - Jared B Becksfort
- Department of Radiation Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105
| | - David A LeVine
- University of TN Health Sciences Center, 881 Madison Ave Ste 1020, Memphis, TN 38163
| | - Yousef Ismael
- Department of Radiation Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105
| | - Kaleb Darrow
- University of TN Health Sciences Center, 881 Madison Ave Ste 1020, Memphis, TN 38163
| | - Vadim P Moskvin
- Department of Radiation Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105
| | - Fakhriddin Pirlepesov
- Department of Radiation Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105
| | - Paul Klimo
- Department of Surgery, Semmes Murphy, 6325 Humphreys Blvd, Memphis, TN 38120; Division of Pediatric Neurosurgery and Associate Professor, The University of Tennessee Health Science Center
| | - Lucas Elijovich
- Department of Neurology, University of TN Health Sciences Center, 847 Monroe Avenue, Suite 226, Memphis, TN 38163
| | - Daniel J Indelicato
- Department of Radiation Oncology, University of Florida, Jacksonville, FL 32206
| | - Fredrick A Boop
- Department of Surgery, Semmes Murphy, 6325 Humphreys Blvd, Memphis, TN 38120; Division of Pediatric Neurosurgery and Associate Professor, The University of Tennessee Health Science Center
| | - Thomas E Merchant
- Department of Radiation Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105
| |
Collapse
|
2
|
Wilson LJ, Pirlepesov F, Moskvin V, Li Z, Guo Y, Li Y, Merchant TE, Faught AM. Proton therapy delivery method affects dose-averaged linear energy transfer in patients. Phys Med Biol 2021; 66. [PMID: 33607632 DOI: 10.1088/1361-6560/abe835] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Accepted: 02/19/2021] [Indexed: 11/11/2022]
Abstract
The dosimetric advantages of proton therapy have led to its rapid proliferation in recent decades. This has been accompanied by a shift in technology from older units that deliver protons by passive scattering (PS) to newer units that increasingly use pencil-beam scanning (PBS). The biologic effectiveness of proton physical dose purportedly rises with increasing dose-weighted average linear energy transfer (LETD). The objective of this study was to determine the extent to which proton delivery methods affect LETD. We calculated LETDfrom simple, dosimetrically matched, and clinical treatment plans with TOPAS Monte-Carlo transport code. Simple treatment plans comprised single fields of PS and PBS protons in a water phantom. We performed simulations of matched and clinical treatment plans by using the treatment and anatomic data obtained from a cohort of children with craniopharyngioma who previously received PS or PBS proton therapy. We compared the distributions of LETDfrom PS and PBS delivery methods in clinically relevant ROIs. Wilcoxon signed-rank tests comparing single fields in water revealed that the LETDvalues from PBS were significantly greater than those from PS inside and outside the targeted volume (p < 0.01). Statistical tests comparing LETD-volume histograms from matched and clinical treatment plans showed that LETDwas generally greater for PBS treatment plans than for PS treatment plans (p < 0.05). In conclusion, the proton delivery method affects LETDboth inside and outside of the target volume. These findings suggest that PBS is more biologically effective than PS. Given the rapid expansion of PBS proton therapy, future studies are needed to confirm the applicability of treatment evaluation methods developed for PS proton therapy to those for modern PBS treatments to ensure their safety and effectiveness for the growing population of patients receiving proton therapy. This study uses data from two clinical trials: NCT01419067 and NCT02792582.
Collapse
Affiliation(s)
- Lydia J Wilson
- St. Jude Children's Research Hospital, Department of Radiation Oncology, Memphis, TN, United States of America
| | - Fakhriddin Pirlepesov
- St. Jude Children's Research Hospital, Department of Radiation Oncology, Memphis, TN, United States of America
| | - Vadim Moskvin
- St. Jude Children's Research Hospital, Department of Radiation Oncology, Memphis, TN, United States of America
| | - Zuofeng Li
- University of Florida Proton Therapy Institute, Department of Radiation Oncology, Jacksonville, FL, United States of America
| | - Yian Guo
- St. Jude Children's Research Hospital, Department of Biostatistics, Memphis, TN, United States of America
| | - Yimei Li
- St. Jude Children's Research Hospital, Department of Biostatistics, Memphis, TN, United States of America
| | - Thomas E Merchant
- St. Jude Children's Research Hospital, Department of Radiation Oncology, Memphis, TN, United States of America
| | - Austin M Faught
- St. Jude Children's Research Hospital, Department of Radiation Oncology, Memphis, TN, United States of America
| |
Collapse
|